Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $60.98 +0.10%
Revenue Growth %: -7.1%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Jabil (JBL) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
